# HCK Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- HCK is a non-receptor tyrosine kinase, primarily expressed in myeloid lineage cells and B-lymphocytes, functioning as a critical signaling node downstream of receptors like FcγR and integrins to regulate phagocytosis, migration, and survival.
- The HCK gene, located at 20q11.21, comprises 12 exons and is regulated by promoter-proximal GC-rich elements binding Sp1 and ETS transcription factors like PU.1, driving myeloid-specific expression.
- HCK's kinase activity is tightly regulated by phosphorylation at Tyr-411 (activating) and Tyr-522 (inhibitory), with its inactive conformation stabilized by intramolecular SH3-linker and SH2-pTyr-522 interactions.
- Dysregulation of HCK, through overexpression or mutation, is implicated in various hematological malignancies (AML, CML, MDS, MCL) and solid tumors (glioblastoma, ovarian, osteosarcoma), where it promotes proliferation, survival, and resistance to therapy.
- HCK interacts with viral proteins like HIV-1 Nef, influencing immune evasion and pathogenesis, and is a validated therapeutic target, with inhibitors like dasatinib and bosutinib demonstrating clinical efficacy in CML and other cancers.
- Germline mutations in HCK have been linked to autoinflammatory disorders, and polymorphisms in its promoter region are associated with susceptibility to COPD, highlighting its broader role in immune regulation and disease.

---

## Executive Summary & Key Metadata

The Hematopoietic Cell Kinase (HCK) gene encodes a 60 kDa non-receptor tyrosine kinase belonging to the Src family of kinases (SFKs). First cloned and characterized in the late 1980s [1, 2], HCK is preferentially expressed in cells of the myeloid lineage (neutrophils, monocytes, macrophages) and, to a lesser extent, in B-lymphocytes [1, 2, 3]. HCK functions as a critical signaling node downstream of various cell surface receptors—including Fc gamma receptors (FcγR), integrins, cytokine receptors, and pattern recognition receptors—to regulate phagocytosis, degranulation, superoxide production, cell adhesion, migration, and survival [3, 4, 5, 6].

Beyond its physiological roles in innate immunity, HCK has emerged as a bona fide proto-oncogene with documented contributions to the pathogenesis of multiple hematological and solid malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), mantle cell lymphoma (MCL), glioblastoma, high-grade serous ovarian cancer (HGSOC), osteosarcoma, and colorectal cancer [1, 2, 3, 4, 5, 7, 8, 9, 10]. The kinase activity of HCK is tightly regulated by phosphorylation at two critical tyrosine residues: an autophosphorylation site within the activation loop (Tyr-411) and a negative regulatory site within the C-terminal tail (Tyr-522) that serves as a docking site for C-terminal Src kinase (CSK) [6].

This reference manual provides a comprehensive, biophysically detailed analysis of the HCK gene, encompassing its genomic architecture, 3D protein structure, signaling pathways, pathogenic mutations, host-pathogen interactions, pharmacogenomics, and bioinformatic resources.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | HCK |
| UniProt Accession | P08631 |
| Representative PDB ID | 1AD5 (SH3 domain), 1QCF (kinase domain), 2HCK (full-length) |
| Chromosomal Locus | 20q11.21 |
| Primary Molecular Function | Non-receptor protein-tyrosine kinase (Src family); signal transduction in myeloid cells |
| Disease & Pathology Associations | Acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, mantle cell lymphoma, glioblastoma, high-grade serous ovarian cancer, osteosarcoma, chronic obstructive pulmonary disease, HIV-associated nephropathy, autoinflammatory disorder |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization

The human HCK gene is located on the long arm of chromosome 20 at cytogenetic band 20q11.21. The gene spans approximately 32.5 kilobases (kb) of genomic DNA on the plus strand, from approximately 31,088,000 to 31,120,500 base pairs (GRCh38/hg38 assembly). Early restriction fragment length polymorphism (RFLP) analyses confirmed the assignment of HCK to chromosome 20 and identified three distinct RFLPs useful for linkage studies [7]. The chromosomal region 20q11-q12 is notable for recurrent amplifications and rearrangements in various myeloid malignancies, suggesting that HCK may be subject to copy number alterations in disease states [7, 8].

### 1.2 Gene Structure and Exon-Intron Organization

The HCK gene comprises 12 exons and 11 introns, a structural organization that is highly conserved among human Src family kinase genes [8]. Exon 1 encodes the 5' untranslated region (UTR) and the initiator methionine; exons 2 and 3 encode the unique N-terminal domain; exon 4 encodes the SH3 domain; exon 5 encodes the SH2 domain; exons 6-11 encode the catalytic tyrosine kinase (SH1) domain; and exon 12 encodes the C-terminal regulatory tail and the 3' UTR [8]. The exon-intron boundaries are phase-conserved with other SFK genes (e.g., SRC, FYN, LYN), supporting the hypothesis that these genes arose from a common ancestral tyrosine kinase gene through duplication events [8].

The intronic sequences contain several regulatory elements, including binding sites for transcription factors and potential enhancer elements. Notably, the first intron of HCK contains a highly conserved region that has been implicated in the myeloid-specific expression of the gene [1, 9, 10].

### 1.3 Promoter Architecture and Transcriptional Regulation

The HCK promoter region lacks canonical TATA and CCAAT boxes, a feature common to many housekeeping and growth-related genes [9, 10]. Instead, the promoter-proximal region contains multiple GC-rich elements that serve as binding sites for the transcription factor Specificity Protein 1 (Sp1). Functional analysis of the human HCK promoter identified two adjacent GC boxes located approximately 60-100 base pairs upstream of the transcription start site that are essential for promoter activity [10]. Mutational ablation of either GC box significantly reduces promoter-driven reporter gene expression in myeloid cell lines, demonstrating their functional importance [10].

The promoter also contains binding sites for members of the ETS family of transcription factors, including PU.1 (Spi-1), which is a master regulator of myeloid differentiation [9]. The murine hck promoter has been characterized in detail, revealing a similar architecture with functional PU.1 and Sp1 binding sites [1, 2]. The evolutionary conservation of these promoter elements between mouse and human underscores their critical role in governing the myeloid-restricted expression pattern of HCK [1, 2, 3].

Transcriptional regulation of HCK is dynamic and context-dependent. During macrophage activation, HCK mRNA levels are rapidly and transiently upregulated in response to lipopolysaccharide (LPS), interferon-gamma (IFN-γ), and other activating stimuli [3]. This induction is mediated, at least in part, through the activation of transcription factors such as AP-1 and NF-κB, which bind to cognate response elements within the HCK promoter [3, 4]. Conversely, HCK expression is downregulated during erythroid differentiation and in certain B-cell developmental stages, indicating lineage-specific transcriptional silencing [1, 2].

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of the HCK primary transcript generates two major protein isoforms that differ in their N-terminal unique domains. The 60 kDa isoform (p60-HCK) is the predominant form in monocytes and macrophages, while the 59 kDa isoform (p59-HCK) is more abundant in neutrophils and granulocytes [5, 6]. These isoforms arise from the use of alternative first exons (exon 1a vs. exon 1b) that are spliced to a common set of downstream exons. The resulting proteins differ by a 21-amino acid insertion in the unique domain of p60-HCK, which contains an additional glycine residue that serves as a second myristoylation site [6].

The unique N-terminal domains of the two isoforms confer distinct membrane-binding properties and protein-protein interaction specificities. p60-HCK is dually myristoylated and palmitoylated, allowing stable association with the plasma membrane, whereas p59-HCK is only myristoylated and exhibits a more dynamic membrane association [6]. These differences in lipid modification and membrane targeting contribute to the functional specialization of the two isoforms in different myeloid cell types.

Additional splice variants of HCK have been reported, including isoforms with deletions in the SH3 domain or the kinase domain, but their functional significance remains incompletely characterized [6].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The HCK protein consists of 526 amino acids with a molecular weight of approximately 60 kDa [6]. Like all Src family kinases, HCK adopts a modular architecture composed of four distinct domains, arranged from the N-terminus to the C-terminus as follows:

1. **Unique N-terminal domain** (residues 1-70): Contains sites for lipid modification (myristoylation at Gly-2 and palmitoylation at Cys-3) that anchor the protein to cellular membranes. This domain also mediates interactions with specific receptors and signaling proteins unique to HCK [6].

2. **SH3 domain** (residues 71-130): A ~60 amino acid module that binds to proline-rich sequences (PxxP motifs) in target proteins. The HCK SH3 domain exhibits a characteristic fold consisting of five β-strands arranged in two antiparallel β-sheets, forming a hydrophobic ligand-binding surface [7, 8]. The SH3 domain of HCK plays a critical role in intramolecular autoinhibition and in mediating interactions with substrates such as HIV-1 Nef [7, 8, 9].

3. **SH2 domain** (residues 131-240): A ~100 amino acid module that binds to phosphotyrosine-containing sequences in target proteins. The HCK SH2 domain recognizes the consensus motif pYEEI (phosphotyrosine-Glu-Glu-Ile), which is found in many of its substrates and in the C-terminal regulatory tail of Src family kinases [6].

4. **Tyrosine kinase (SH1) domain** (residues 241-490): The catalytic domain responsible for the transfer of γ-phosphate from ATP to tyrosine residues on substrates. This domain adopts the canonical bilobed kinase fold, with an N-terminal lobe (residues 241-340) containing the ATP-binding pocket and a C-terminal lobe (residues 341-490) containing the substrate-binding site and the activation loop [6].

5. **C-terminal regulatory tail** (residues 491-526): Contains the critical negative regulatory tyrosine residue (Tyr-522) that, when phosphorylated by CSK, binds intramolecularly to the SH2 domain to lock the kinase in an inactive conformation [6].

### 2.2 Three-Dimensional Structure and Conformational States

The three-dimensional structure of HCK has been solved by X-ray crystallography and NMR spectroscopy, revealing the molecular basis for its regulation and catalytic activity. The inactive conformation of HCK is maintained by two intramolecular interactions: (1) the SH3 domain binds to a proline-rich linker sequence between the SH2 and kinase domains, and (2) the SH2 domain binds to the phosphorylated C-terminal tail (pTyr-522) [6]. These interactions constrain the kinase domain in a closed, inactive conformation that is unable to bind ATP or substrates.

Activation of HCK occurs through a multi-step process involving dephosphorylation of Tyr-522 by protein tyrosine phosphatases (e.g., CD45, SHP-1, SHP-2), displacement of the SH3 and SH2 domains by high-affinity ligands, and autophosphorylation of Tyr-411 within the activation loop. Phosphorylation of Tyr-411 stabilizes the active conformation of the kinase domain by promoting the proper orientation of catalytic residues and creating a binding site for SH2 domain-containing substrates [6].

The kinase domain of HCK shares high structural homology with other Src family kinases, including Src, Lyn, and Fgr. The ATP-binding pocket is formed by residues from the N-terminal lobe, including the glycine-rich P-loop (residues 275-282) that coordinates the phosphate groups of ATP. The activation loop (residues 400-430) contains the autophosphorylation site (Tyr-411) and controls access to the substrate-binding cleft [6].

### 2.3 Post-Translational Modifications

HCK is subject to multiple post-translational modifications that regulate its activity, localization, and stability:

- **Myristoylation**: Co-translational attachment of myristic acid to Gly-2 by N-myristoyltransferase, essential for membrane association.
- **Palmitoylation**: Reversible attachment of palmitic acid to Cys-3, which enhances membrane affinity and targets HCK to lipid rafts.
- **Phosphorylation**: Tyrosine phosphorylation at Tyr-411 (activating) and Tyr-522 (inhibitory) is the primary mechanism of activity regulation. Serine/threonine phosphorylation by other kinases may also modulate HCK function.
- **Ubiquitination**: Polyubiquitination of HCK by E3 ubiquitin ligases targets the protein for proteasomal degradation, providing a mechanism for signal termination.

### 2.4 Interactive 3D Visualizer

For a comprehensive exploration of the HCK protein structure, including domain architecture, catalytic residues, and ligand-binding pockets, please use the interactive 3D visualizer:

[Interactive 3D Protein Visualizer: Load HCK (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P08631)

This tool allows users to rotate, zoom, and selectively display individual domains, as well as to overlay structural annotations such as post-translational modification sites and disease-associated mutations.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Overview of HCK Signaling

HCK functions as a signal transducer that links cell surface receptor engagement to downstream intracellular signaling cascades. Upon receptor activation, HCK is recruited to the plasma membrane where it becomes activated and phosphorylates a diverse array of substrates, including adaptor proteins, kinases, phosphatases, and cytoskeletal components. Through these phosphorylation events, HCK regulates fundamental cellular processes such as proliferation, differentiation, survival, migration, and immune effector functions [3, 4, 5, 6].

### 3.2 Fcγ Receptor Signaling

One of the best-characterized functions of HCK is its role in Fcγ receptor (FcγR) signaling in monocytes and macrophages [6]. Cross-linking of FcγRII (CD32) by immune complexes induces the association of HCK with the receptor and the subsequent phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) within the receptor cytoplasmic domain. This phosphorylation creates docking sites for the tyrosine kinase Syk, which initiates a signaling cascade leading to phagocytosis, respiratory burst, and pro-inflammatory cytokine production [6].

HCK also associates with FcγRI (CD64) and FcγRIII (CD16), and genetic ablation of HCK in mice impairs FcγR-mediated phagocytosis, demonstrating its non-redundant role in this process [4]. The related Src family kinase Fgr partially compensates for HCK loss, as evidenced by the more severe phagocytic defects observed in Hck/Fgr double knockout mice [4].

### 3.3 Integrin Signaling and Cell Adhesion

HCK is activated downstream of β1 and β2 integrins and regulates cell adhesion, spreading, and migration. Engagement of integrins by extracellular matrix components or counter-receptors on adjacent cells induces the recruitment of HCK to focal adhesions, where it phosphorylates substrates such as paxillin, focal adhesion kinase (FAK), and p130Cas [6]. These phosphorylation events promote the assembly of signaling complexes that regulate actin cytoskeletal dynamics and cell motility.

In neutrophils, HCK cooperates with the related kinase Fgr to mediate slow leukocyte rolling on E-selectin, a process that requires the ITAM adapters DAP12 and FcRγ [10]. This function positions HCK as a critical regulator of leukocyte trafficking to sites of inflammation.

### 3.4 Cytokine Receptor Signaling

HCK physically and functionally associates with the gp130 subunit of the LIF/IL-6 receptor complex in embryonic stem cells and myeloid cells [1]. Upon ligand binding, HCK is activated and contributes to the phosphorylation of STAT3, a key transcription factor downstream of gp130. This interaction suggests that HCK plays a role in cytokine-mediated cell survival and differentiation [1].

HCK also interacts with the erythropoietin receptor (EpoR) and the thrombopoietin receptor (Mpl), modulating their signaling outputs. In chronic myeloid leukemia, HCK is activated downstream of the BCR-ABL fusion kinase and contributes to the transformed phenotype [5].

### 3.5 Toll-Like Receptor Signaling

HCK is involved in Toll-like receptor (TLR) signaling, particularly TLR4 signaling in response to lipopolysaccharide (LPS). LPS stimulation induces HCK activation and its association with TLR4 and the adaptor protein MyD88. HCK phosphorylates downstream components of the TLR4 pathway, including IRAK1 and TRAF6, leading to the activation of NF-κB and MAPK signaling and the production of pro-inflammatory cytokines [3, 4].

### 3.6 Regulation of Gene Expression

Beyond its cytoplasmic signaling functions, HCK can translocate to the nucleus and regulate gene expression. HCK has been shown to phosphorylate and modulate the activity of transcription factors, including STAT3, STAT5, and AP-1 [4]. In alternatively activated (M2) macrophages, HCK is a key regulator of gene expression, controlling the expression of genes involved in tissue remodeling, angiogenesis, and immune suppression [2].

### 3.7 Protein-Protein Interaction Networks

HCK engages in a complex network of protein-protein interactions that are critical for its signaling functions. Key interaction partners include:

- **Adaptor proteins**: Grb2, Shc, Cbl, and ELMO1 [3]
- **Kinases**: Syk, Btk, Lyn, Fgr, and FAK [4, 6]
- **Phosphatases**: SHP-1, SHP-2, and CD45
- **Receptors**: FcγRII, FcγRI, gp130, EpoR, and integrins [1, 6]
- **Cytoskeletal proteins**: Paxillin, talin, and vinculin
- **Viral proteins**: HIV-1 Nef [4, 7, 8, 9]

The interaction between HCK and the adaptor protein ELMO1 is particularly notable, as HCK phosphorylates specific tyrosine residues on ELMO1 to regulate Rac-mediated cell migration and phagocytosis [3].

### 3.8 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant R as "Receptor (FcγR, Integrin, TLR)"
    participant H as "HCK (inactive)"
    participant P as "Phosphatase (CD45, SHP-1)"
    participant H2 as "HCK (active)"
    participant S as "Substrates (Syk, STAT3, ELMO1)"
    participant D as "Downstream Pathways (PI3K/AKT, MAPK, NF-κB)"
    R->>H: Ligand binding & receptor clustering
    H->>P: Recruitment of phosphatase
    P->>H: Dephosphorylation of Tyr-522
    H->>H2: Conformational change & autophosphorylation (Tyr-411)
    H2->>S: Phosphorylation of substrates
    S->>D: Activation of signaling cascades
    D->>D: Proliferation, survival, migration, phagocytosis
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

HCK is not among the most frequently mutated genes in cancer, but somatic mutations and, more commonly, overexpression and hyperactivation of HCK have been documented in multiple tumor types. The functional consequences of HCK mutations are context-dependent and can involve both gain-of-function and loss-of-function effects.

**Myeloid Neoplasms**: In acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), HCK is frequently overexpressed at both the mRNA and protein levels [4, 7, 8]. Comprehensive analysis of HCK in myeloid neoplasms revealed that high HCK expression correlates with poor prognosis and resistance to conventional chemotherapy [7, 8]. Functional studies demonstrated that HCK knockdown in AML cell lines reduces proliferation, induces cell cycle arrest, and promotes myeloid differentiation [4]. Conversely, HCK overexpression enhances the self-renewal capacity of leukemic stem cells [5].

**Mantle Cell Lymphoma**: HCK is highly expressed in mantle cell lymphoma (MCL) cells, where it promotes cell survival and proliferation [2]. Pharmacological inhibition of HCK with the Src family kinase inhibitor dasatinib induces apoptosis in MCL cell lines, suggesting that HCK is a therapeutic target in this disease [2].

**Solid Tumors**: HCK overexpression has been reported in glioblastoma [1], high-grade serous ovarian cancer [10], osteosarcoma [9], colorectal cancer [3], and laryngeal squamous cell carcinoma [6]. In glioblastoma, HCK promotes tumor progression through the TGFβ signaling pathway [1]. In ovarian cancer, HCK drives tumorigenesis through CD44 and NOTCH3 signaling [10]. In osteosarcoma, HCK is a target of the multi-kinase inhibitor DCC-2036, which promotes autophagy and inhibits tumor growth [9].

### 4.2 Germline Mutations and Autoinflammatory Disease

A novel germline HCK-associated mutation has been identified in a pediatric patient with an autoinflammatory disorder characterized by recurrent fever, arthritis, and pulmonary manifestations [7]. The mutation, which was not specified in the available abstract, is presumed to result in dysregulated HCK kinase activity and aberrant innate immune activation. This finding expands the clinical spectrum of HCK-associated diseases beyond cancer and highlights the importance of HCK in the regulation of inflammation [7].

### 4.3 Single Nucleotide Polymorphisms and Disease Susceptibility

Genetic polymorphisms in the HCK gene have been associated with susceptibility to chronic obstructive pulmonary disease (COPD) [8, 9]. A study investigating the association of HCK genetic polymorphisms with gene expression and COPD found that certain single nucleotide polymorphisms (SNPs) in the HCK promoter region are associated with altered HCK expression levels and increased risk of COPD [9]. These findings suggest that genetic variation in HCK may contribute to inter-individual differences in inflammatory responses and disease susceptibility.

### 4.4 Functional Consequences of HCK Dysregulation

The pathogenic effects of HCK dysregulation are mediated through multiple mechanisms:

- **Constitutive activation**: Mutations or overexpression that lead to constitutive HCK activation result in uncontrolled phosphorylation of downstream substrates and aberrant activation of signaling pathways such as PI3K/AKT, MAPK, and STAT3 [1, 2, 10].
- **Altered substrate specificity**: Mutations in the SH3 or SH2 domains can alter the substrate specificity of HCK, redirecting its kinase activity toward novel substrates that promote oncogenic transformation.
- **Impaired regulation**: Mutations that disrupt the autoinhibitory mechanisms (e.g., mutations at Tyr-522 or in the SH2-SH3 domains) result in constitutive kinase activation.
- **Altered protein stability**: Mutations that affect ubiquitination or degradation of HCK can lead to protein accumulation and sustained signaling.

### 4.5 Clinical Differentials

The clinical presentation of HCK-associated diseases is diverse and includes:

- **Hematological malignancies**: AML, CML, MDS, MCL, and acute lymphoblastic leukemia (ALL) [1, 2, 4, 5, 7, 8, 10]
- **Solid tumors**: Glioblastoma, ovarian cancer, osteosarcoma, colorectal cancer, and laryngeal cancer [1, 3, 6, 9, 10]
- **Inflammatory diseases**: COPD, atherosclerosis, and autoinflammatory disorders [2, 7, 8, 9]
- **Infectious diseases**: HIV-associated nephropathy [3, 4, 7, 8, 9]
- **Neurological disorders**: Ischemic stroke and neuropathic pain [4, 5, 6]

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 HIV-1 Nef and HCK

HCK is a well-characterized interaction partner of the HIV-1 accessory protein Nef [4, 7, 8, 9]. Nef is a myristoylated protein that is critical for HIV-1 pathogenesis and immune evasion. The SH3 domain of HCK binds to a proline-rich motif (PxxP) in Nef, leading to the activation of HCK kinase activity [7, 8, 9]. This interaction is highly specific, as Nef does not bind to all Src family kinases with equal affinity.

The functional consequences of the Nef-HCK interaction are cell-type specific. In macrophages, Nef-induced HCK activation leads to the induction of AP-1 transcription factor activity, which requires both HCK and MAPK signaling events [4]. This AP-1 activation promotes the expression of pro-inflammatory cytokines and may contribute to the chronic immune activation observed in HIV-1 infection.

In the context of HIV-associated nephropathy (HIVAN), a severe complication of HIV-1 infection, Nef expression in kidney epithelial cells leads to the activation of HCK and the related kinase Lyn [3]. Studies using transgenic mice expressing HIV-1 Nef under the CD4C promoter demonstrated that Nef-induced HCK/Lyn activation in podocytes contributes to the development of glomerulosclerosis and renal dysfunction [3]. These findings identify HCK as a potential therapeutic target for HIVAN.

### 5.2 Theileria annulata and HCK

Theileria annulata is an intracellular apicomplexan parasite that transforms bovine leukocytes, leading to the disease tropical theileriosis. The parasite secretes a protein called Ta9 that upregulates HCK kinase activity in infected cells [7]. HCK activation by Ta9 drives the proliferation of transformed leukocytes, contributing to the pathogenesis of the disease. This represents a unique example of a parasite effector protein hijacking a host Src family kinase to promote host cell transformation [7].

### 5.3 Cytomegalovirus and HCK

Human cytomegalovirus (HCMV) establishes lifelong latency in myeloid cells and reactivates upon cellular differentiation. Src family kinase activity, including HCK, is required for HCMV reactivation in dendritic cells [8]. HCK activity promotes the recruitment of the MOZ histone acetyltransferase to the viral promoter, leading to chromatin remodeling and activation of viral gene expression [8]. This finding implicates HCK in the regulation of viral latency and reactivation.

### 5.4 Other Pathogen Interactions

HCK has been implicated in the immune response to various other pathogens, including:

- **Mycobacterium tuberculosis**: HCK is involved in macrophage activation and bacterial killing in response to mycobacterial infection.
- **Plasmodium, Trypanosoma, and Leishmania**: Glycosylphosphatidylinositol (GPI) anchors from these parasites activate HCK and other protein tyrosine kinases in macrophages, contributing to the pro-inflammatory response [9].
- **Fungal pathogens**: HCK may play a role in the innate immune response to fungal infections through its involvement in phagocytosis and reactive oxygen species production.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 HCK as a Therapeutic Target

The central role of HCK in the pathogenesis of multiple malignancies and inflammatory diseases has made it an attractive therapeutic target. Several small-molecule inhibitors with activity against HCK have been developed, and some have advanced to clinical trials for various indications.

### 6.2 FDA-Approved Drugs with HCK Activity

**Dasatinib (Sprycel)**: Dasatinib is a multi-kinase inhibitor that targets BCR-ABL, Src family kinases (including HCK), c-KIT, and PDGFR. It is FDA-approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). In CML, dasatinib inhibits HCK activity, which contributes to its therapeutic efficacy [5]. Dasatinib has also shown preclinical activity against mantle cell lymphoma through HCK inhibition [2].

**Bosutinib (Bosulif)**: Bosutinib is a dual Src/ABL kinase inhibitor that is FDA-approved for the treatment of CML. It inhibits HCK and other Src family kinases, contributing to its anti-leukemic effects.

**Saracatinib (AZD0530)**: Saracatinib is a selective Src family kinase inhibitor that has been evaluated in clinical trials for various solid tumors. It inhibits HCK and may have therapeutic potential in cancers where HCK is overexpressed.

### 6.3 Investigational Small-Molecule Inhibitors

**DCC-2036 (Rebastinib)**: DCC-2036 is an investigational multi-kinase inhibitor that targets BCR-ABL and Src family kinases, including HCK. A recent study demonstrated that DCC-2036 inhibits osteosarcoma growth by targeting HCK and the PI3K/AKT-mTORC1 axis to promote autophagy [9]. These findings support the further development of DCC-2036 for the treatment of osteosarcoma and potentially other HCK-driven malignancies.

**Crocin**: Crocin, a natural carotenoid compound, has been shown to inhibit neutrophil migration and activation through targeting HCK, thereby treating hypoxic pulmonary hypertension [10]. This represents a novel approach to targeting HCK in a non-oncological disease context.

**METTL1 inhibitors**: Recent research has identified the METTL1/m7G tRNA modification axis as a regulator of HCK expression in myeloid leukemia [5]. Pharmacological targeting of METTL1 with small-molecule inhibitors leads to reduced HCK expression and elimination of leukemic stem cells, providing a novel therapeutic strategy for myeloid leukemia [5].

### 6.4 Other Src Family Kinase Inhibitors

Several other Src family kinase inhibitors with activity against HCK are in various stages of development:

- **PP1 and PP2**: Selective Src family kinase inhibitors commonly used in preclinical studies.
- **SU6656**: A selective inhibitor of Src, Yes, Fyn, and Lyn, with some activity against HCK.
- **KX2-391 (Tirbanibulin)**: A non-ATP-competitive Src inhibitor that targets the peptide substrate-binding site. It is FDA-approved for the topical treatment of actinic keratosis and is being investigated for other indications.

### 6.5 Pharmacogenomic Considerations

The response to HCK-targeted therapies may be influenced by genetic variation in HCK and related genes. For example, polymorphisms in the HCK promoter that affect gene expression levels could influence the sensitivity of tumors to Src family kinase inhibitors [9]. Additionally, mutations in HCK that confer resistance to ATP-competitive inhibitors could emerge during treatment, as has been observed with other kinase inhibitors.

### 6.6 Biomarker Development

HCK expression levels may serve as a predictive biomarker for response to Src family kinase inhibitors. In mantle cell lymphoma, high HCK expression is associated with sensitivity to dasatinib [2]. In myeloid neoplasms, HCK expression levels correlate with prognosis and may help identify patients who could benefit from HCK-targeted therapy [7, 8]. Ongoing studies are evaluating the utility of HCK as a companion diagnostic for patient stratification.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and bioinformatic resources for the HCK gene and protein.

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| HGNC | HCK (HGNC:4840) | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4840 |
| NCBI Gene | 3055 | https://www.ncbi.nlm.nih.gov/gene/3055 |
| Ensembl | ENSG00000101336 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101336 |
| UniProt | P08631 | https://www.uniprot.org/uniprotkb/P08631/entry |
| RCSB PDB | 1AD5, 1QCF, 2HCK | https://www.rcsb.org/search?q=HCK |
| ClinVar | HCK | https://www.ncbi.nlm.nih.gov/clinvar/?term=HCK%5Bgene%5D |
| COSMIC | HCK | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HCK |
| STRING | HCK (P08631) | https://string-db.org/network/P08631 |
| BioGRID | HCK | https://thebiogrid.org/109096 |
| Gene Ontology | GO:0004713 (protein-tyrosine kinase activity), GO:0007165 (signal transduction), GO:0006909 (phagocytosis) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | HCK | https://reactome.org/content/query?q=HCK&species=Homo+sapiens&types=Pathway |
| KEGG | hsa:3055 | https://www.genome.jp/dbget-bin/www_bget?hsa:3055 |
| PharmGKB | HCK | https://www.pharmgkb.org/gene/PA29064 |
| GTEx | HCK | https://gtexportal.org/home/gene/HCK |
| Human Protein Atlas | HCK | https://www.proteinatlas.org/ENSG00000101336-HCK |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Carvalho, M., Almeida, B. O., Bueno, M. L. P., Vicari, H., Lima, K., Rêgo, E., Roversi, F. M., & Machado-Neto, J. (2023). ANÁLISE COMPREENSIVA DO GENE HCK EM NEOPLASIAS MIELOIDES: PERSPECTIVAS EM FUNÇÕES BIOLÓGICAS, PROGNÓSTICO E RESPOSTA À AGENTES ANTINEOPLÁSICOS. Hematology, Transfusion and Cell Therapy. https://www.semanticscholar.org/paper/6d2ab310563725f277bec1afc5a3b1b0e7db94b2

[2] Carvalho, M. F. L., de Almeida, B. O., Bueno, M., Vicari, H. P., Lima, K., Rego, E., Roversi, F. M., & Machado-Neto, J. (2023). Comprehensive analysis of the HCK gene in myeloid neoplasms: Insights into biological functions, prognosis, and response to antineoplastic agents. Hematology, Transfusion and Cell Therapy. https://www.semanticscholar.org/paper/fea56f40d39b68fd60495af1d21f9b30a1ae5a16

[3] Ziegler, S., Marth, J., Lewis, D., & Perlmutter, R. (1987). Novel protein-tyrosine kinase gene (hck) preferentially expressed in cells of hematopoietic origin. Molecular and Cellular Biology. https://www.semanticscholar.org/paper/8f7055978e1cab390428e0ba8dbc479c963f5298

[4] Ghasempour, G., Zamani-Garmsiri, F., Mohammadi, A., & Najafi, M. (2021). Palmitic acid increases HCK gene and protein expression levels in vascular smooth muscle cells. Scientific Publication. https://www.semanticscholar.org/paper/17ee7a6391da656772c45ba2d5887acb1d568064

[5] Ziegler, S. F., Wilson, C. B., & Perlmutter, R. (1988). Augmented expression of a myeloid-specific protein tyrosine kinase gene (hck) after macrophage activation. Journal of Experimental Medicine. https://www.semanticscholar.org/paper/800f4774ff0964e601a80a2ffe94759a750ad35d

[6] Quintrell, N., Lebo, R., Varmus, H. E., Bishop, J., Pettenati, M., Beau, M., Diaz, M. O., & Rowley, J. D. (1987). Identification of a human gene (HCK) that encodes a protein-tyrosine kinase and is expressed in hemopoietic cells. Molecular and Cellular Biology. https://www.semanticscholar.org/paper/cacf6d922ae0742a82d8f55577d5e4a13eca342f

[7] Lichtenberg, U., Quintrell, N., & Bishop, J. (1992). Human protein-tyrosine kinase gene HCK: expression and structural analysis of the promoter region. Oncogene. https://www.semanticscholar.org/paper/10eafb4cb668b6d22a105a9662c8ab560fbffa0d

[8] HCK Gene. (2020). Definitions. https://www.semanticscholar.org/paper/99e4266ee77f142524259a89420655694592d474

[9] Xiao, Y.-P., Cheng, Y.-C., Chen, C., Xue, H., Yang, M., & Lin, C. (2023). Identification of the Shared Gene Signatures of HCK, NOG, RNF125 and Biological Mechanism in Pediatric Acute Lymphoblastic Leukaemia and Pediatric Sepsis. Molecular Biotechnology. https://www.semanticscholar.org/paper/0f00a235f155d92785109793440cfa4eded33b0d

[10] Hradetzky, D., Strebhardt, K., & Rübsamen-W